Skip to Content

2,350 Results Found

  • Article
  • Open Access
13 Citations
3,904 Views
18 Pages

PARP10 Mediates Mono-ADP-Ribosylation of Aurora-A Regulating G2/M Transition of the Cell Cycle

  • Simone Di Paola,
  • Maria Matarese,
  • Maria Luisa Barretta,
  • Nina Dathan and ,
  • Antonino Colanzi,
  • Daniela Corda and
  • Giovanna Grimaldi
  • + 2 authors+ 0 author

24 October 2022

Intracellular mono-ADP-ribosyltransferases (mono-ARTs) catalyze the covalent attachment of a single ADP-ribose molecule to protein substrates, thus regulating their functions. PARP10 is a soluble mono-ART involved in the modulation of intracellular s...

(This article belongs to the Special Issue PARP Enzymes, ADP-Ribose and NAD+ Metabolism in Cancer)
  • Communication
  • Open Access
13 Citations
4,494 Views
11 Pages

15 March 2021

Poly-ADP-ribose polymerase (PARP)-family ADP-ribosyltransferases function in various signaling pathways, predominantly in the nucleus and cytosol. Although PARP inhibitors are in clinical practice for cancer therapy, the enzymatic activities of indiv...

(This article belongs to the Special Issue Protein Mono-ADP-Ribosylation in the Control of Cell Functions)
  • Review
  • Open Access
123 Citations
13,923 Views
23 Pages

PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling

  • Lotte van Beek,
  • Éilís McClay,
  • Saleha Patel,
  • Marianne Schimpl and ,
  • Laura Spagnolo and
  • Taiana Maia de Oliveira
  • + 1 author+ 0 author

Poly (ADP-ribose) polymerases (PARP) 1-3 are well-known multi-domain enzymes, catalysing the covalent modification of proteins, DNA, and themselves. They attach mono- or poly-ADP-ribose to targets using NAD+ as a substrate. Poly-ADP-ribosylation (PAR...

(This article belongs to the Section Molecular Biology)
  • Article
  • Open Access
2 Citations
1,005 Views
20 Pages

Structural Determinants of PARP1 Selectivity from Molecular Dynamics Analysis of PARP1 and PARP2 Complexes

  • Dmitrii O. Shkil,
  • Natalia A. Chesnokova,
  • Andrey A. Ivashchenko,
  • Elena V. Petersen and
  • Philipp Y. Maximov

Selective inhibition of poly(ADP-ribose) polymerase 1 (PARP1) may reduce the hematologic toxicity associated with dual PARP1/PARP2 inhibition. We performed molecular dynamics simulations for five selective inhibitors in complexes with PARP1 and PARP2...

(This article belongs to the Section Computational and Theoretical Chemistry)
  • Review
  • Open Access
104 Citations
12,522 Views
16 Pages

PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs

  • Luyao Wang,
  • Chao Liang,
  • Fangfei Li,
  • Daogang Guan and ,
  • Xiaoqiu Wu,
  • Xuekun Fu,
  • Aiping Lu and
  • Ge Zhang
  • + 3 authors+ 0 author

8 October 2017

Poly (ADP-ribose) polymerase 1 (PARP1), the best-studied isoform of the nuclear enzyme PARP family, plays a pivotal role in cellular biological processes, such as DNA repair, gene transcription, and so on. PARP1 has been found to be overexpressed in...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
3 Citations
2,709 Views
18 Pages

Aminomethylmorpholino Nucleosides as Novel Inhibitors of PARP1 and PARP2: Experimental and Molecular Modeling Analyses of Their Selectivity and Mechanism of Action

  • Irina Chernyshova,
  • Inna Vasil’eva,
  • Nina Moor,
  • Nikita Ivanisenko and ,
  • Mikhail Kutuzov,
  • Tatyana Abramova,
  • Alexandra Zakharenko and
  • Olga Lavrik
  • + 3 authors+ 0 author

22 November 2024

Poly(ADP-ribose) polymerases 1 and 2 (PARP1 and PARP2) play a key role in DNA repair. As major sensors of DNA damage, they are activated to produce poly(ADP-ribose). PARP1/PARP2 inhibitors have emerged as effective drugs for the treatment of cancers...

(This article belongs to the Special Issue Advances in Enzyme Inhibitors: Mechanisms, Applications, and Future Perspectives)
  • Review
  • Open Access
65 Citations
8,621 Views
18 Pages

Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies

  • José Yélamos,
  • Lucia Moreno-Lama,
  • Jaime Jimeno and
  • Syed O. Ali

8 February 2020

Poly(ADP-ribose) polymerase-1 (PARP-1) and PARP-2 are enzymes which post-translationally modify proteins through poly(ADP-ribosyl)ation (PARylation)—the transfer of ADP-ribose chains onto amino acid residues—with a resultant modulation of...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Review
  • Open Access
7 Citations
5,340 Views
21 Pages

Leveraging PARP-1/2 to Target Distant Metastasis

  • Mallory I. Frederick,
  • Djihane Abdesselam,
  • Anna Clouvel,
  • Laurent Croteau and
  • Saima Hassan

20 August 2024

Poly (ADP-Ribose) Polymerase (PARP) inhibitors have changed the outcomes and therapeutic strategy for several cancer types. As a targeted therapeutic mainly for patients with BRCA1/2 mutations, PARP inhibitors have commonly been exploited for their c...

(This article belongs to the Special Issue Cancer Biology: From Genetic Aspects to Treatment)
  • Article
  • Open Access
8 Citations
3,771 Views
11 Pages

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes

  • Natalya Maluchenko,
  • Darya Koshkina,
  • Anna Korovina,
  • Vasily Studitsky and
  • Alexey Feofanov

23 October 2022

Inhibitors (PARPi) of poly(ADP-ribose-)polymerase-1 (PARP1) are used in antitumor therapy; their cytotoxicity correlates with the efficiency of PARP1 trapping in cell chromatin. Previous studies have demonstrated the PARPi-induced trapping of PARP1 o...

(This article belongs to the Special Issue DNA Damage Response Regulation and Cancer)
  • Article
  • Open Access
8 Citations
3,568 Views
13 Pages

Investigation of the Complexes Formed between PARP1 Inhibitors and PARP1 G-Quadruplex at the Gene Promoter Region

  • Sabrina Dallavalle,
  • Salvatore Princiotto,
  • Luce M. Mattio,
  • Roberto Artali and ,
  • Loana Musso,
  • Anna Aviñó,
  • Ramon Eritja,
  • Claudio Pisano,
  • Raimundo Gargallo and
  • Stefania Mazzini
  • + 5 authors+ 0 author

14 August 2021

DNA repair inhibitors are one of the latest additions to cancer chemotherapy. In general, chemotherapy produces DNA damage but tumoral cells may become resistant if enzymes involved in DNA repair are overexpressed and are able to reverse DNA damage....

(This article belongs to the Special Issue The Polymorphic World of G-Quadruplexes: From Structural Insights to Functional Activity-2nd Edition)
  • Article
  • Open Access
18 Citations
7,024 Views
21 Pages

Silencing of PARP2 Blocks Autophagic Degradation

  • Laura Jankó,
  • Zsanett Sári,
  • Tünde Kovács,
  • Gréta Kis and ,
  • Magdolna Szántó,
  • Miklós Antal,
  • Gábor Juhász and
  • Péter Bai
  • + 3 authors+ 0 author

7 February 2020

Poly(ADP-Ribose) polymerases (PARPs) are enzymes that metabolize NAD+. PARP1 and PARP10 were previously implicated in the regulation of autophagy. Here we showed that cytosolic electron-dense particles appear in the cytoplasm of C2C12 myoblasts in wh...

(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease)
  • Review
  • Open Access
37 Citations
6,766 Views
16 Pages

Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes

  • Ramya Ambur Sankaranarayanan,
  • Susanne Kossatz,
  • Wolfgang Weber,
  • Mohsen Beheshti and ,
  • Agnieszka Morgenroth and
  • Felix M. Mottaghy
  • + 1 author+ 0 author

The central paradigm of novel therapeutic approaches in cancer therapy is identifying and targeting molecular biomarkers. One such target is the nuclear DNA repair enzyme Poly-(ADP ribose) polymerase 1 (PARP1). Sensitivity to PARP inhibition in certa...

(This article belongs to the Special Issue Emerging Technologies for Medical Imaging - Diagnostics, Monitoring and Therapy of Cancers)
  • Review
  • Open Access
122 Citations
12,474 Views
16 Pages

8 February 2020

Poly (ADP-ribose) polymerase (PARP) 1 is an essential molecule in DNA damage response by sensing DNA damage and docking DNA repair proteins on the damaged DNA site through a type of posttranslational modification, poly (ADP-Ribosyl)ation (PARylation)...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Article
  • Open Access
7 Citations
3,374 Views
13 Pages

Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD

  • Jun Tang,
  • Víctor Curull,
  • Xuejie Wang,
  • Coral Ampurdanés and ,
  • Xavier Duran,
  • Lara Pijuan,
  • Alberto Rodríguez-Fuster,
  • Rafael Aguiló,
  • José Yélamos and
  • Esther Barreiro
  • + 5 authors+ 0 author

11 November 2020

(1) Background: Lung cancer (LC) is a major leading cause of death worldwide. Poly (ADP-ribose) polymerase (PARP)-1 and PARP-2 are key players in cancer. We aimed to assess PARP-1 and PARP-2 expression and activity and DNA damage in tumors and non-tu...

(This article belongs to the Section Cancer Pathophysiology)
  • Review
  • Open Access
49 Citations
8,132 Views
26 Pages

The Multifactorial Role of PARP-1 in Tumor Microenvironment

  • Juan Manuel Martí,
  • Mónica Fernández-Cortés,
  • Santiago Serrano-Sáenz,
  • Esteban Zamudio-Martinez and ,
  • Daniel Delgado-Bellido,
  • Angel Garcia-Diaz and
  • Francisco Javier Oliver
  • + 2 authors+ 0 author

20 March 2020

Poly(ADP-ribose) polymerases (PARPs), represent a family of 17 proteins implicated in a variety of cell functions; some of them possess the enzymatic ability to synthesize and attach poly (ADP-ribose) (also known as PAR) to different protein substrat...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Abstract
  • Open Access
1,639 Views
2 Pages

Differences in Durability of PARP Inhibition by PARP Inhibitors in Ovarian Cancer Cells

  • Hannah Louise Smith,
  • Asima Mukhopadhyay,
  • Yvette Drew,
  • Elaine Willmore and
  • Nicola Curtin

Background: PARP inhibitors (PARPi) exploit defects in homologous recombination repair (HRR) to selectively kill tumour cells. Continuous PARP inhibition is required for cytotoxicity. PARPis rucaparib, olaparib, and niraparib have been approved for u...

(This article belongs to the Proceedings of The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response)
  • Review
  • Open Access
117 Citations
14,596 Views
18 Pages

PARP inhibitors are the first clinically approved drugs that were developed based on synthetic lethality. PARP inhibitors have shown promising outcomes since their clinical applications and have recently been approved as maintenance treatment for can...

(This article belongs to the Special Issue Drug Resistance in Cancer: Molecular Mechanisms and Tackling Strategies)
  • Review
  • Open Access
39 Citations
8,707 Views
19 Pages

PARP-1-Associated Pathological Processes: Inhibition by Natural Polyphenols

  • Natalya V. Maluchenko,
  • Alexey V. Feofanov and
  • Vasily M. Studitsky

23 October 2021

Poly (ADP-ribose) polymerase-1 (PARP-1) is a nuclear enzyme involved in processes of cell cycle regulation, DNA repair, transcription, and replication. Hyperactivity of PARP-1 induced by changes in cell homeostasis promotes development of chronic pat...

(This article belongs to the Special Issue Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach)
  • Article
  • Open Access
3 Citations
2,013 Views
17 Pages

Background/Objectives: PARP inhibitors (PARPis) currently play frontline roles in the management of prostate, pancreatic, ovarian and breast cancers, but their roles in colorectal cancer (CRC) management have yet to be clarified. Importantly, the spe...

(This article belongs to the Special Issue Precision Oncology: Targeting Molecular Subtypes in Cancer Therapy)
  • Article
  • Open Access
12 Citations
3,400 Views
12 Pages

The Prognostic Values of PARP-1 Expression in Uveal Melanoma

  • Malgorzata Gajdzis,
  • Stamatios Theocharis,
  • Jerzy Klijanienko,
  • Nathalie Cassoux and ,
  • Sophie Gardrat,
  • Piotr Donizy,
  • Radoslaw Kaczmarek and
  • Pawel Gajdzis
  • + 3 authors+ 0 author

31 January 2021

Background: Uveal melanoma is the most common primary intraocular malignancy in adults. In advanced cases, the prognosis is very poor. Thus far, no effective methods of pharmacotherapy of this cancer have been found. The aim of the study was to evalu...

(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease 2020)
  • Article
  • Open Access
19 Citations
6,353 Views
25 Pages

Design, Synthesis and Molecular Modeling Study of Conjugates of ADP and Morpholino Nucleosides as A Novel Class of Inhibitors of PARP-1, PARP-2 and PARP-3

  • Yuliya V. Sherstyuk,
  • Nikita V. Ivanisenko,
  • Alexandra L. Zakharenko,
  • Maria V. Sukhanova and ,
  • Roman Y. Peshkov,
  • Ilia V. Eltsov,
  • Mikhail M. Kutuzov,
  • Tatiana A. Kurgina,
  • Ekaterina A. Belousova and
  • Tatyana V. Abramova
  • + 8 authors+ 3 authors

27 December 2019

We report on the design, synthesis and molecular modeling study of conjugates of adenosine diphosphate (ADP) and morpholino nucleosides as potential selective inhibitors of poly(ADP-ribose)polymerases-1, 2 and 3. Sixteen dinucleoside pyrophosphates c...

(This article belongs to the Special Issue Inhibition of DNA Repair Enzymes as a Valuable Pharmaceutical Approach)
  • Review
  • Open Access
108 Citations
30,336 Views
16 Pages

PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?

  • Amanda F. Swindall,
  • Jennifer A. Stanley and
  • Eddy S. Yang

26 July 2013

Oxidative stress induced by reactive oxygen species can result in DNA damage within cells and subsequently increase risk for carcinogenesis. This may be averted by repair of DNA damage through the base or nucleotide excision repair (BER/NER) pathways...

(This article belongs to the Special Issue Role of Oxidatively-Induced DNA Damage in Carcinogenesis)
  • Review
  • Open Access
131 Citations
24,883 Views
24 Pages

30 March 2019

Poly (ADP-ribose) polymerases (PARPs) play an important role in various cellular processes, such as replication, recombination, chromatin remodeling, and DNA repair. Emphasizing PARP’s role in facilitating DNA repair, the PARP pathway has been a targ...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
8 Citations
3,827 Views
22 Pages

15 February 2023

The protein PARP1, which plays a crucial role in DNA repair processes, is an attractive target for cancer therapy, especially for BRCA-deficient cancers. To overcome the acquired drug resistance of PARP1, PARP1 G-quadruplex (G4) identified in the PAR...

(This article belongs to the Special Issue Spectroscopic, Thermodynamic and Molecular Docking Studies on Molecular Mechanisms of Drug Binding to Proteins II)
  • Article
  • Open Access
23 Citations
3,906 Views
20 Pages

Functional Roles of PARP2 in Assembling Protein–Protein Complexes Involved in Base Excision DNA Repair

  • Inna Vasil’eva,
  • Nina Moor,
  • Rashid Anarbaev,
  • Mikhail Kutuzov and
  • Olga Lavrik

Poly(ADP-ribose) polymerase 2 (PARP2) participates in base excision repair (BER) alongside PARP1, but its functions are still under study. Here, we characterize binding affinities of PARP2 for other BER proteins (PARP1, APE1, Polβ, and XRCC1) and oli...

(This article belongs to the Special Issue Molecular Mechanisms Safeguarding Genome Integrity in DNA Replication, Repair and Transcription)
  • Review
  • Open Access
82 Citations
11,335 Views
16 Pages

PARP1: Liaison of Chromatin Remodeling and Transcription

  • Wen Zong,
  • Yamin Gong,
  • Wenli Sun,
  • Tangliang Li and
  • Zhao-Qi Wang

27 August 2022

Poly(ADP-ribosyl)ation (PARylation) is a covalent post-translational modification and plays a key role in the immediate response of cells to stress signals. Poly(ADP-ribose) polymerase 1 (PARP1), the founding member of the PARP superfamily, synthesiz...

(This article belongs to the Special Issue PARP Enzymes, ADP-Ribose and NAD+ Metabolism in Cancer)
  • Review
  • Open Access
22 Citations
7,141 Views
32 Pages

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers

  • Abdullah Alhusaini,
  • Aoife Cannon,
  • Stephen G. Maher,
  • John V. Reynolds and
  • Niamh Lynam-Lennon

Gastrointestinal (GI) malignancies are a major global health burden, with high mortality rates. The identification of novel therapeutic strategies is crucial to improve treatment and survival of patients. The poly (ADP-ribose) polymerase (PARP) enzym...

(This article belongs to the Special Issue Biomarkers and New Therapeutical Strategies for Cancer Diagnosis and Treatment)
  • Review
  • Open Access
10 Citations
5,095 Views
11 Pages

The emergence of PARP inhibitors as a therapeutic strategy for tumors with high genomic instability, particularly those harboring BRCA mutations, has advanced cancer treatment. However, recent advances have illuminated a multifaceted role of PARP1 be...

(This article belongs to the Special Issue The Role of Inflammatory Cytokines in Cancer Progression 2.0)
  • Article
  • Open Access
13 Citations
4,515 Views
25 Pages

Targeting PARP-1 and DNA Damage Response Defects in Colorectal Cancer Chemotherapy with Established and Novel PARP Inhibitors

  • Philipp Demuth,
  • Lea Thibol,
  • Anna Lemsch,
  • Felix Potlitz and ,
  • Lukas Schulig,
  • Christoph Grathwol,
  • Georg Manolikakes,
  • Dennis Schade,
  • Vassilis Roukos and
  • Jörg Fahrer
  • + 6 authors+ 1 author

10 October 2024

The DNA repair protein PARP-1 emerged as a valuable target in the treatment of tumor entities with deficiencies of BRCA1/2, such as breast cancer. More recently, the application of PARP inhibitors (PARPi) such as olaparib has been expanded to other c...

(This article belongs to the Section Cancer Therapy)
  • Article
  • Open Access
8 Citations
4,882 Views
11 Pages

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling

  • Hannah L. Smith,
  • Elaine Willmore,
  • Asima Mukhopadhyay,
  • Yvette Drew and
  • Nicola J. Curtin

12 November 2022

Six PARP inhibitors (PARPi) are approved for cancer therapy as monotherapy agents in daily or twice-daily continuous dosing schedules to maintain the necessary continuous suppression of PARP activity. Continuous PARP inhibition is required for single...

  • Review
  • Open Access
53 Citations
9,057 Views
21 Pages

The Nucleolus and PARP1 in Cancer Biology

  • Marina Engbrecht and
  • Aswin Mangerich

6 July 2020

The nucleolus has been known for a long time to fulfill crucial functions in ribosome biogenesis, of which cancer cells can become addicted to in order to produce sufficient amounts of proteins for cell proliferation. Recently, the nucleolus has emer...

(This article belongs to the Special Issue PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer)
  • Review
  • Open Access
55 Citations
9,143 Views
21 Pages

PARP Inhibitors in Breast and Ovarian Cancer

  • Samuel S. Y. Wang,
  • Yeo Ee Jie,
  • Sim Wey Cheng,
  • Goh Liuh Ling and
  • Heong Valerie Yue Ming

18 April 2023

Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most...

(This article belongs to the Collection Targeting Solid Tumors)
  • Article
  • Open Access
1 Citations
1,925 Views
16 Pages

Development of Mitochondria-Targeted PARP Inhibitors

  • Pavels Dimitrijevs,
  • Marina Makrecka-Kuka and
  • Pavel Arsenyan

19 January 2026

PARP inhibitors are a clinically validated class of anticancer therapeutics that exploit synthetic lethality to target homologous recombination-deficient tumors, such as those carrying BRCA1/2 mutations. Nevertheless, the rational design of mitochond...

(This article belongs to the Section Biological Factors)
  • Feature Paper
  • Review
  • Open Access
68 Citations
10,367 Views
25 Pages

25 July 2020

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, D...

(This article belongs to the Special Issue Preclinical and Clinical Advances in Ovarian Cancer)
  • Article
  • Open Access
6 Citations
3,376 Views
19 Pages

Phase Separation of FUS with Poly(ADP-ribosyl)ated PARP1 Is Controlled by Polyamines, Divalent Metal Cations, and Poly(ADP-ribose) Structure

  • Maria V. Sukhanova,
  • Rashid O. Anarbaev,
  • Konstantin N. Naumenko,
  • Loic Hamon and ,
  • Anastasia S. Singatulina,
  • David Pastré and
  • Olga I. Lavrik
  • + 2 authors+ 0 author

20 November 2024

Fused in sarcoma (FUS) is involved in the formation of nuclear biomolecular condensates associated with poly(ADP-ribose) [PAR] synthesis catalyzed by a DNA damage sensor such as PARP1. Here, we studied FUS microphase separation induced by poly(ADP-ri...

(This article belongs to the Section Molecular Biophysics)
  • Article
  • Open Access
11 Citations
6,180 Views
17 Pages

Characterization of PARP6 Function in Knockout Mice and Patients with Developmental Delay

  • Anke Vermehren-Schmaedick,
  • Jeffrey Y. Huang,
  • Madison Levinson,
  • Matthew B. Pomaville and ,
  • Sarah Reed,
  • Gary A. Bellus,
  • Fred Gilbert,
  • Boris Keren,
  • Delphine Heron and
  • Michael S. Cohen
  • + 12 authors+ 7 authors

22 May 2021

PARP6, a member of a family of enzymes (17 in humans) known as poly-ADP-ribose polymerases (PARPs), is a neuronally enriched PARP. While previous studies from our group show that Parp6 is a regulator of dendrite morphogenesis in rat hippocampal neuro...

(This article belongs to the Special Issue Protein Mono-ADP-Ribosylation in the Control of Cell Functions)
  • Article
  • Open Access
4 Citations
2,186 Views
19 Pages

Non-Classical H1-like PARP1 Binding to Chromatosome

  • Daria Koshkina,
  • Natalya Maluchenko,
  • Dmitry Nilov,
  • Alexander Lyubitelev and ,
  • Anna Korovina,
  • Sergey Pushkarev,
  • Grigoriy Armeev,
  • Mikhail Kirpichnikov,
  • Vasily Studitsky and
  • Alexey Feofanov
  • + 5 authors+ 0 author

25 August 2025

Poly(ADP-ribose)polymerase 1 (PARP1) is an enzyme that interacts with chromatin during DNA repair and transcription processes; the molecular mechanisms of these processes remain to be determined. Previously, we have shown that PARP1 can bind to and r...

(This article belongs to the Special Issue Epigenetics and DNA Repair: Regulatory Mechanisms and Therapeutic Opportunities)
  • Article
  • Open Access
7 Citations
3,034 Views
11 Pages

Resveratrol Inhibits Nucleosome Binding and Catalytic Activity of PARP1

  • Daria O. Koshkina,
  • Natalya V. Maluchenko,
  • Anna N. Korovina,
  • Angelina A. Lobanova and ,
  • Alexey V. Feofanov and
  • Vasily M. Studitsky
  • + 1 author+ 0 author

2 November 2024

The natural polyphenol resveratrol is a biologically active compound that interacts with DNA and affects the activity of some nuclear enzymes. Its effect on the interaction between nucleosomes and poly(ADP-ribose) polymerase-1 (PARP1) and on the cata...

(This article belongs to the Section Molecular Medicine)
  • Review
  • Open Access
11 Citations
5,084 Views
25 Pages

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

  • Andrisha-Jade Inderjeeth,
  • Monique Topp,
  • Elaine Sanij,
  • Elena Castro and
  • Shahneen Sandhu

30 November 2022

Approximately a quarter of men with metastatic castrate resistant prostate cancer (mCRPC) have alterations in homologous recombination repair (HRR). These patients exhibit enhanced sensitivity to poly(ADP-ribose) polymerase (PARP) inhibitors. Leverag...

(This article belongs to the Special Issue Clinical Use of PARP Inhibitors in Cancer – From Bench to Bedside and Back Again)
  • Review
  • Open Access
4 Citations
3,675 Views
15 Pages

[18F]F-Poly(ADP-Ribose) Polymerase Inhibitor Radiotracers for Imaging PARP Expression and Their Potential Clinical Applications in Oncology

  • Honest Ndlovu,
  • Ismaheel O. Lawal,
  • Sipho Mdanda,
  • Mankgopo M. Kgatle and ,
  • Kgomotso M. G. Mokoala,
  • Akram Al-Ibraheem and
  • Mike M. Sathekge
  • + 2 authors+ 0 author

11 June 2024

Including poly(ADP-ribose) polymerase (PARP) inhibitors in managing patients with inoperable tumors has significantly improved outcomes. The PARP inhibitors hamper single-strand deoxyribonucleic acid (DNA) repair by trapping poly(ADP-ribose)polymeras...

(This article belongs to the Section Nuclear Medicine & Radiology)
  • Article
  • Open Access
16 Citations
6,496 Views
16 Pages

Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer

  • Pranabananda Dutta,
  • Kimberly Paico,
  • Gabriela Gomez,
  • Yanyuan Wu and
  • Jaydutt V. Vadgama

21 May 2020

Background: PolyADP ribosylation (PARylation) by PARP1 is a significant post-translational modification affecting protein function in various cancers. However, PARP1 mediated cellular processes in the context of breast cancer are not fully understood...

  • Article
  • Open Access
29 Citations
6,377 Views
19 Pages

Post-Transcriptional Regulation of PARP7 Protein Stability Is Controlled by Androgen Signaling

  • Teddy Kamata,
  • Chun-Song Yang,
  • Tiffany A. Melhuish,
  • Henry F. Frierson Jr. and ,
  • David Wotton and
  • Bryce M. Paschal
  • + 1 author+ 0 author

9 February 2021

Poly-ADP-ribose polymerases (PARPs) are enzymes that catalyze ADP-ribosylation and play critical roles in normal and disease settings. The PARP family member, PARP7, is a mono-ADP-ribosyltransferase that has been suggested to play a tumor suppressive...

(This article belongs to the Special Issue Protein Mono-ADP-Ribosylation in the Control of Cell Functions)
  • Review
  • Open Access
147 Citations
15,875 Views
20 Pages

The Enigmatic Function of PARP1: From PARylation Activity to PAR Readers

  • Tatiana Kamaletdinova,
  • Zahra Fanaei-Kahrani and
  • Zhao-Qi Wang

12 December 2019

Poly(ADP-ribosyl)ation (PARylation) is catalysed by poly(ADP-ribose) polymerases (PARPs, also known as ARTDs) and then rapidly removed by degrading enzymes. Poly(ADP-ribose) (PAR) is produced from PARylation and provides a delicate and spatiotemporal...

(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease)
  • Article
  • Open Access
25 Citations
5,497 Views
13 Pages

Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents

  • Dong Zhou,
  • Huaping Chen,
  • Cedric Mpoy,
  • Sadia Afrin and ,
  • Buck E. Rogers,
  • Joel R. Garbow,
  • John A. Katzenellenbogen and
  • Jinbin Xu
  • + 3 authors+ 0 author

Poly (ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme in the DNA repair process and the target of several FDA-approved inhibitors. Several of these inhibitors have been radiolabeled for non-invasive imaging of PARP-1 expression or targeted rad...

(This article belongs to the Section Drug Discovery and Development)
  • Review
  • Open Access
75 Citations
10,130 Views
29 Pages

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”

  • Stergios Boussios,
  • Afroditi Karathanasi,
  • Deirdre Cooke,
  • Cherie Neille and ,
  • Agne Sadauskaite,
  • Michele Moschetta,
  • Nikolaos Zakynthinakis-Kyriakou and
  • Nicholas Pavlidis
  • + 3 authors+ 0 author

Poly (ADP-ribose) polymerase (PARP) inhibitors are a novel class of therapeutic agents that target tumors with deficiencies in the homologous recombination DNA repair pathway. Genomic instability characterizes high-grade serous ovarian cancer (HGSOC)...

(This article belongs to the Special Issue Ovarian Cancer: Characteristics, Screening, Diagnosis and Treatment)
  • Review
  • Open Access
176 Citations
27,008 Views
25 Pages

12 November 2012

Poly (ADP-ribose) polymerase 1 (PARP1) is an ADP-ribosylating enzyme essential for initiating various forms of DNA repair. Inhibiting its enzyme activity with small molecules thus achieves synthetic lethality by preventing unwanted DNA repair in the...

(This article belongs to the Special Issue DNA Damage Response)
  • Review
  • Open Access
25 Citations
7,886 Views
33 Pages

6 September 2020

Modulation of PARP1 expression, changes in its enzymatic activity, post-translational modifications, and inflammasome-dependent cleavage play an important role in the development of monocytes and numerous subtypes of highly specialized macrophages. T...

(This article belongs to the Special Issue Molecular Role of PARP in Health and Disease 2020)
  • Article
  • Open Access
618 Views
11 Pages

PET Imaging of New Target PARP in Prostate Cancer

  • Zhao Yang,
  • Wei Wang,
  • Xuanyi Dai,
  • Liya Wei and ,
  • Yanli Li,
  • Wenfeng Gou and
  • Feifei Xu
  • + 2 authors+ 0 author

30 June 2026

Background/Objectives: Poly (ADP-ribose) polymerase (PARP), particularly PARP-1, is overexpressed in prostate cancer and linked to poor prognosis. PARP inhibitors show efficacy in homologous recombination deficiency (HRD)-positive tumors, but 30&ndas...

  • Review
  • Open Access
21 Citations
6,794 Views
18 Pages

5 June 2022

PARP1 enzyme plays an important role in DNA damage recognition and signalling. PARP inhibitors are approved in breast, ovarian, pancreatic, and prostate cancers harbouring a pathogenic variant in BRCA1 or BRCA2, where PARP1 inhibition results mainly...

(This article belongs to the Special Issue A Deeper Dive into Signaling Pathways in Cancers)
  • Review
  • Open Access
8 Citations
5,287 Views
15 Pages

30 January 2024

The principal understanding of the Poly(ADP-ribose) polymerase (PARP) regulation of genomes has been focused on its role in DNA repair; however, in the past few years, an additional role for PARPs and PARylation has emerged in regulating viral-host i...

(This article belongs to the Special Issue ADP-Ribosylation in Pathogens)

of 47